When a 61-year-old woman died recently after having received an accepted targeted treatment—known as stereotactic body-radiation therapy—doctors had to start re-thinking both the radiation dose and the treatment itself.
Non-small-cell lung carcinoma (Photo credit: Wikipedia)
Months after she’d received the treatment for early-stage adenocarcinoma, a type of non-small cell lung cancer, the woman came back suffering. Doctors found not only that her cancer had metastasized but also that a large portion of healthy tissue in her airway had been destroyed by the radiation. They then treated her with chemotherapy rather than radiation, but she died anyway a few months later.
Despite doctors following accepted protocol, the patient died. It took courage to report this case, according to the US News and Health article. Even though this incident is about a single patient, having it on the record can help other doctors think more carefully about how and how much to use this increasingly popular therapy.
Let us hope physicians are all as brave and forthcoming if and when they discover dangerous or devastating side effects from the new nanoparticle-based targeted cancer therapy techniques.
Most deaths from cancer come after the primary tumor has been treated—usually with some combination of surgery and chemo or radiation—when stray cancer cells from the tumor escape and spread to other parts of the body (metastasis).
Image via Wikipedia
Since not all cells from cancer tumors behave the same way or have the same DNA, researchers have been looking for a way to study single cells. The problem was separating them. Now this new nanoparticle approach uses magnets to detect whether cells are growing, dividing or dying. It spins the cells in a magnetic field where each type rotates at a different speed. Larger, dying or dividing cells rotate more slowly and in specific patterns. so they can be separated into a group of single cells. Thus the researcher can focus on investigating the behavior of those particular cells.
One of the big promises of this approach is that scientists may now be able to test drugs on just the cells themselves instead of on the entire human organism—thus avoiding some of the worst side effects for patients. And, instead of throwing everything they have at the patient in hopes of affecting the disease, doctors can work with the cells and then with greater confidence prescribe medicine they’ve been able to test as working best for this individual person.
What a blessing for cancer patients this will be.